The aim of DECISION (Digoxin Evaluation in Chronic Heart Failure) is by means of a large study to investigate the effect of low doses of Digoxin added to the treatment of heart failure.
Heart failure is a serious heart disease that occurs frequently. It is estimated that 1 in 5 people suffer from heart failure. The symptoms associated with it are fluid accumulation, poor condition and shortness of breath. The prognosis for these patients is poor and it often means (re)hospitalisation for the patient.
The medicine Dixogine is the oldest and cheapest medicine for treating heart failure, but its use has declined sharply in recent years. There are several reasons for this. An important one is a study that showed that patients treated with high doses of digoxin did not perform better than patients without this drug (placebo). However, further research has shown that patients treated with low doses of digoxin did have a better life expectancy.
ZonMW/Hartstichting has provided a 3 million euro grant from the Good Use of Medicines programme to the research consortium, which is led by professors Dirk Jan van Veldhuisen, Peter van der Meer and Michiel Rienstra, who will carry out the DECISION study. The professors are all connected to the Cardiology department of the UMCG. They want to show that patients with heart failure who are treated with low doses of digoxin, are less likely to be re-admitted to hospital and die less quickly as a result of heart failure.
- UMCG coordinates this project
- ZonMW – Good Use of Medicines – Big Trials